Abstract: Purpose/Background: For a drug to acquire Food and Drug Administration approval, it must significantly outperform placebo treatment. In recent years, the placebo effect seems to be increasing in neuropsychiatric conditions. Here, we examine placebo effects across self-reported, clinically rated, and performance-based data from a trial using a corticotropin-releasing hormone receptor type 1 (CRHR1) antagonist for treatment of post-traumatic stress disorder (PTSD).
1
To receive US Food and Drug Administration (FDA) approval, generally, a drug treatment must be more efficacious than a placebo. It is thought that response to placebo is a complex behavioral phenomenon often beyond patient control, producing significant improvement with biological correlates. 2 This phenomenon is known as the placebo effect.
The placebo effect has always had a significant presence in mental health research trials, but now seems to be increasing in both clinician-rated and self-reported measures. Trials for selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine showed considerable efficacy for major depressive disorder as well as many anxiety disorders in the 1980s and 1990s. Since the time of the first approvals for SSRIs, the drug-placebo difference, even for previously approved treatments, has steadily declined on average and the number of failed trials has increased. 3, 4 The cause of this increase remains largely unknown, although it has been suggested that changing characteristics of patients entering clinical trials over the past 30 years may be associated with an increase in placebo effects. An alternative suggestion has been that efforts to recruit patients who meet entry criteria may have led to biased rating with inflation of clinical symptoms at baseline.
Psychiatric patients may be particularly likely to demonstrate placebo effects in clinical trials. Recent depression studies report placebo response rates of 25% to 60% on the primary outcomes measures. 5 In contrast, hypertension studies typically show an improvement in blood pressure readings of approximately 5% from baseline while taking a placebo. 6 This discrepancy of placebo effect magnitude across diseases emerges in part from the lack of an objective biomarker for depression; clinical assessments are clearly more prone to multiple sources of bias compared with an objective measure such as blood pressure.
Post-traumatic stress disorder (PTSD) is an illness marked by a variety of reexperiencing, avoidance, mood, and cognitive symptoms after exposure to a traumatic event, as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition. The lifetime prevalence of PTSD in the United States is estimated to be 6.8%, with women more often affected than men. 7, 8 Patients with PTSD suffer from decreased functioning across a broad spectrum of psychosocial domains, including occupational and interpersonal relationships. 9 Studies have revealed a significant correlation between self-reported functional impairment and self-reported distress. 10 Furthermore, PTSD has a high rate of comorbid substance abuse and depression. 11 Given the high degree of comorbidity, it is difficult to assess the specific impact of PTSD on the functionality and well-being of a patient.
Since PTSD was first recognized as a psychiatric disorder, treatment has revolved around psychotherapeutic techniques. Cognitive-processing therapy and prolonged exposure therapies are forms of cognitive behavioral therapy proven to have efficacy for treating PTSD, although rates of treatment nonresponse reach 50%. 12 Pharmacologic options for PTSD remain limited. Currently, SSRIs, sertraline and paroxetine, are the only FDAapproved pharmacotherapies for PTSD. Remission rates from SSRI treatment for PTSD are typically below 30%. 13 Clearly, more research and development are needed to improve PTSD treatment outcomes.
The analyses reported herein are based on data collected from participants in a clinical trial for a novel drug treatment for PTSD (NCT01018992). Post-traumatic stress disorder, along with other anxiety-related illnesses, may be associated with chronically increased activity of central nervous system circuits utilizing corticotropin-releasing hormone (CRH). A broad literature implicates elevated CRH activity in PTSD.
14 Corticotropin-releasing hormone signaling drives activation of the hypothalamic-pituitaryadrenal (HPA) axis, resulting in increased release of adrenocorticotropin and cortisol, which may have adverse psychiatric effects when sustained. In response to stress, corticotropin-releasing factor (CRF) is released from the hypothalamus and goes on to activate the HPA axis. Corticotropin-releasing factor binds in the pituitary gland to stimulate the release of adrenocorticotropin hormone, which enters the systemic circulation and stimulates the adrenal cortex to release cortisol. Cortisol then typically has a negative feedback effect on the HPA axis. In PTSD patients, the levels of circulating adrenocorticotropin hormone and cortisol seem to be low, thus elevating CRF levels. Corticotropin-releasing factor receptors are numerous in the amygdala, where activation induces a fear response. Intracerebroventricular administration of CRH produces anxiety-like behaviors in animal models, including features particularly relevant to PTSD such as sleep disturbance, enhanced acoustic startle response, and increased conditioned fear response.
14 To target the HPA axis, this trial evaluated GSK561679, a CRH type 1 receptor antagonist versus placebo. 15 Animal models suggest that CRHR1 antagonists may have therapeutic value in the treatment of stress-related disorders, but these agents had not previously been investigated in patients with PTSD. Functional activity and in vitro binding assays indicate that GSK561679 is a potent CRHR1 antagonist. GSK561679 is an investigational drug and is not currently FDA-approved for any indication. Commonly reported adverse events in human studies of GSK561679 have included headache, fatigue, somnolence, dizziness, nausea, nasal congestion, upper respiratory tract infection, influenza, and acne and have been mild in nature. However, in human studies, degenerative changes of the testes were observed in rats, dogs, and cynomolgus monkeys, although the change was reversible after a period of drug withdrawal. This concern has led to the exclusion of men from clinical trials using GSK561679. 14 The main results of the study were negative in that GSK561679 was essentially indistinguishable from placebo, as outlined in the primary results paper from the trial. 15 The baseline scores on the Clinician-Administered PTSD Scale (CAPS) and other tested measures were comparable with other positive trials for PTSD, such as those with venlafaxine, suggesting that the failure of GSK561679 was not a result of symptom severity or placebo responsiveness. Furthermore, there are data suggesting that the CRF pathway is not associated with anxiety-related disorders. The failure of the trial may have been a result of a poor target. 15 Herein, we focus on placebo effects in this negative study across self-reported, clinician-rated, and performance-based assessments. We assumed that the 3 assessment modalities would have different degrees of susceptibility to the placebo response.
Potential drivers of placebo effects on self-report measures include optimism about treatment efficacy and potentially overendorsing symptoms at entry into the study to ensure inclusion. The clinician assessment via clinician-administered ratings could possibly reduce response bias in terms of both baseline symptoms and clinical change, although clinician-based assessments still depend on the participants' verbal responses. 3, 16 However, clinician ratings may also be particularly prone to placebo effects, as evidenced by increased placebo response over time in depression trials using clinical ratings as the outcome measure. Performance-based measures such as cognitive tests seem to be least likely to be susceptible to expectation bias. Although there is a controversy as to whether PTSD patients manifest impairments in cognitive performance that exceed premorbid functioning, 17 cognitive assessments have been shown in other conditions to have placebo effects that are relatively small, on the order of 0.1 to 0.2 SD at a single retesting. 18 In this study, we also included a measure of response bias that examined tendencies toward endorsing symptoms not part of the PTSD syndrome, previously used to detect exaggerated symptom reporting. 10 This measure was examined for its correlation with both baseline and change scores across the different assessment modalities. We hypothesized that the self-reported measures and clinician rated measures would be most susceptible to placebo effects and cognitive test performance least susceptible. In addition, we hypothesized that tendencies toward higher baseline scores on the measure of response bias would be correlated with greater placebo response across all 3 assessment strategies. 
METHODS Participants
Full details of the study protocol have been published previously and are reviewed briefly here. 14 The trial randomized 128 women, with 96 completing the 6-week treatment period. The demographic and clinical characteristics of the randomized sample are presented in Table 1 . Men were excluded from this trial owing to preclinical data suggesting adverse effects of GSK561679 on the male reproductive tract. Participants were recruited across 4 sites: University of California San Francisco; Emory University School of Medicine, Atlanta; Mount Sinai School of Medicine, New York; Michael E. Debakey VA Medical Center/Baylor College of Medicine, Houston. Key inclusion criteria were a diagnosis of chronic PTSD according to the DSM-IV criteria and at least moderately severe PTSD symptom severity, indicated by a CAPS past-week and past-month scores greater than or equal to 50. 19 Exclusion criteria included a diagnosis of a psychotic disorder, bipolar disorder, obsessive compulsive disorder, anorexia nervosa, bulimia, substance abuse or dependence (in the past 90 days), high current suicide risk, being pregnant or nursing, taking psychoactive medication (other than nonbenzodiazepine hypnotics), active legal issues related to PTSD or trauma exposure, or participating in structured psychotherapy targeting PTSD symptoms. All study procedures were done in compliance with the Declaration of Helsinki and its amendments. The institutional review boards of each site approved the study, and all participants signed a written informed consent form before any study procedures being performed.
Measures
Self-reported PTSD symptom severity was assessed using the PTSD Symptom Scale-Self-Report version (PSS-SR 20 ), a 17-item questionnaire that reflects the DSM-IV PTSD symptoms, on a 0 to 3 scale. Clinician-rated PTSD symptom severity was assessed using the CAPS, a structured interview with established reliability and validity. 21 The CAPS assesses the 17 DSM-IV criterion symptoms for PTSD using a 5-point ratings scale from 0 (never) to 4 (daily) for both the frequency and intensity of each symptom. Total scores range from 0 to 136. Depression severity was measured using the Montgomery Asberg Depression Rating Scale (MADRS 22 ), a clinician-rated scale consisting of 10 items. The Symptom Validity Index is a 6-item measure designed to assess the validity and overreporting of subject responses that was embedded in the version of the PSS-SR used in the trial. 23 Each item of the Index is unrelated to PTSD symptoms as defined by the DSM-IV. The 6 items are rated on the same 0 to 3 scale as the PSS-SR.
Self-reported disability was examined with the Sheehan Disability Scale (SDS 24 ), as assessment developed to measure disability in work, social relationships, and family life. The PSS-SR, CAPS, and MADRS were administered at time of screening, then visits V3 to V6, and visits V9 to V11. The SDS was administered at visits 3 and 9.
Performance-Based Assessments
Cognition was examined with a modified version of the MATRICS consensus cognitive battery (MCCB 25, 26 ). The MCCB has 9 different neurocognitive tests and examines 5 different domains of cognitive performance, including verbal memory, spatial memory, working memory, reasoning and problem solving, and processing speed. All of these cognitive domains have been examined in PTSD patients in the past, 17 although meta-analyses of performance have implicated memory impairments as a primary deficit in PTSD. We calculated a composite score, an average of 9 age-corrected t scores based on the MCCB normative program, as our critical dependent variable. The norms program was developed with a comprehensive study of healthy individuals stratified across a wide range of age, sex, and ethnic characteristics.
The ability to perform everyday functional skills, known as functional capacity, was assessed using the Brief version of the University of California at San Diego Performance-based Skills Assessment (UPSA-B
27
). The UPSA-B is a measure of functional capacity in which patients are asked to perform everyday tasks related to communication and finances. The UPSA-B raw scores are converted into a total score ranging from 0 to 100, with higher scores indicating better functioning. Testers administering the MCCB and UPSA-B across all sites were trained in person by one of the authors (P.H.).
Statistical Analysis
In these analyses, we first present a repeated-measures analysis of variance, wherein we examined the effects of treatment group (Active, Placebo) Â time (Baseline, Endpoint) for each of the variables. We then examined the change scores within each treatment group with paired t tests, to determine the effect sizes for time-related changes across self-report, clinicianrated, and performance-based measures. Pearson-product moment correlations were computed between the change scores to determine if change scores within the same assessment modality were more highly intercorrelated than those correlations that crossed assessment modalities.
RESULTS
For 6 of the 7 variables presented in Table 2 , the effect of time was statistically significant, all F 1,92 > 53.02 and all P < 0.001. The only variable without a significant time effect was the UPSA-B, F 1,92 = 0.67 and P = 0.42. However, the interaction of group Â time was nonsignificant for all of the variables, all F 1,92 < 0.71 and all P > 0.40. As shown in Table 2 , the changes from baseline to endpoint were significant using paired t tests for all variables in both groups, other than for the UPSA-B. The effect sizes for changes in the placebo group were quite substantial, ranging from 0.63 to 1.70. Similarly large effect sizes were seen in the GSK561679 treatment group, ranging from 0.26 to 2.62. Consistent with our hypotheses, both self-reported and clinically rated symptoms had similarly large effect sizes for change and even the MCCB changed significantly, but considerably less, at retest. Of note, symptom severity on both the MADRS and CAPS was considerable, with mean scores on the CAPS exceeding the minimum entry criteria by 25 points and MADRS scores on average in the range consistent with major depression. In contrast is the finding that, on average, the sample of PTSD patients did not manifest neuropsychological test performance consistent with impairment (t < 40). There were 21% of the cases whose scores were below 40, but these scores could be consistent with lifelong levels of performance.
We calculated correlations between the baseline and change scores in the entire sample, as there were no treatment effects (Table 3) . Baseline scores on the clinician-rated and self-report measures were all significantly intercorrelated, with shared variance ranging from 14% to 38%. The MCCB and UPSA-B scores were significantly intercorrelated, but there was essentially no shared variance between the MCCB or UPSA scores and any of the clinician-rated or self-reported symptom or disability measures. Validity scores did not share variance with either of the performance-based measures but shared variance with all self-reported and clinician-rated variables. The amount of variance shared with validity scores was notably less than the overlap among the clinician rated and self reported symptom measures.
Changes in the CAPS shared variance with changes in all other self-reported and clinically rated variables, with a 50% overlap with changes in the MADRS (Fig. 1) . Changes in the PSS-SR also shared 50% variance with changes in the MADRS and shared 13% to 17% with changes in the validity index and the SDS. There was essentially no overlapping variance between changes on the MCCB and any of the clinician-rated or self-reported symptom variables or the validity index (Fig. 1) .
We performed 2 final analyses. In the first, we examined the correlations of baseline scores on the validity index and change scores on the other variables, and in the second, we examined how many patients manifested a substantial improvement in their MCCB scores at the single retest assessment. The correlations between baseline scores on the validity index and changes on the other clinically rated, self-reported, and performance-based assessments were nonsignificant (all r < 0.18 and all P > 0.12), other than the correlation between baseline scores and changes on the validity index itself (r = 0.47, P < 0.001). When the distribution of change scores on the MCCB was examined, it was found that 25% of the participants manifested an improvement of 5 or more t score points (0.5 SD based on normative standards) when they were retested. No participants worsened by 5 t score points or more. To retest for regression to the mean, we correlated baseline and change scores on the MCCB composite score. The correlation was statistically significant and positive (r = 0.33, P < 0.001), suggesting that better baseline performers had more improvements. This result was confirmed by comparing performance of patients whose baseline score was above and below the median with a t test, finding that patients whose median scores were above the mean had larger improvements (t(76) = 2.48, P < 0.005).
DISCUSSION
There are several potentially important findings in this study. First is the finding of a substantial placebo effect across both selfreported and clinician-rated PTSD symptoms, everyday functioning, and depression rating scales. As one may have predicted based on major depressive disorder (MDD) trials, clinician ratings were similarly influenced by placebo effect when compared with self-report measures. Second, we did not find that scores on the Symptom Validity Index, designed to identify exaggerated reporting of symptoms, could predict placebo response. Thus, high endorsement of symptoms unrelated to PTSD did not predict increased response to inactive treatment and does not provide a potential screening tool. Third, the placebo effect was also detectable on performance-based measures, although the magnitude of the effect was markedly less. Finally, consistent with our analysis of the baseline data in the study, there was no association between changes in self-reported disability and changes in direct measures of cognitive and functional skills. Thus, both baseline scores and changes in self-reported disability do not manifest any substantial relationship with objective indices of these elements of functioning.
The previous findings largely replicate previous PTSD treatment trials, both positive and negative in their results. Numerous double-blind placebo-controlled studies with agents including atypical antipsychotics and antidepressants have failed to find efficacy in treatment due to large placebo effect on CAPS assessments; however, there were several studies where the active and placebo treatment separated significantly, despite changes in the placebo group of over 1.0 SD. 4, 15, 28 Thus, it is possible to identify a pharmacological treatment for PTSD that exceeds placebo responses, but a large response is clearly required. Notably, this trial was the first to use a CRF antagonist to treat PTSD. It may be that CRF antagonists are only useful in PTSD patients with certain genetic predisposition. Furthermore, there is evidence in the literature that the CRH pathway is not associated with anxiety-related disorders. Future drug trials for PTSD must be constructed to minimize placebo responses as much as possible, but drug selection is also paramount.
Our study is unique in that a significant improvement in cognition while on a placebo was detected. Modest improvements in performance-based measures during a clinical trial are not unusual, but these improvements tend to average 0.1 to 0.2 SD per retest assessment. In this trial, the average retest effect of 0.6 SD was detected. Furthermore, a substantial proportion (25%) of participants in the current trial demonstrated an increase in MCCB score equivalent to 8 intelligence quotient points, considered a clinically meaningful level of improvement. This level of improvement exceeds typical standards for retest effects in either neuropsychiatric conditions or healthy controls. 25 One possibility for these substantial improvements with reassessment may be that study participants had minimal previous experience with performance-based psychological assessments. Completing a neuropsychological test can lead to an increase in familiarity and comfort with the assessment process at the time of the second assessment, which may result in score improvements. Consequently, using performance-based assessments does not obviate placebo effects.
Placebo effects are not unique to PTSD. A meta-analysis done by Khin et al 29 in 2011 evaluated 25 years of MDD placebocontrolled trials and found that only 53% of trials were successful, largely owing to significant and increasing placebo effects. Little research has been done comparing the size of placebo effects in PTSD compared with MDD; however, this would be an interesting area of future research.
The women participating in the study were not receiving any psychotherapy or pharmacologic therapy at the time of entry into the trial, so the process of entering into the treatment structure of a clinical trial may have elicited strong placebo effects. The psychoeducational effects patients receive through trial participation may provide meaningful therapeutic benefits that contribute to placebo-associated symptom reduction. Furthermore, the unexpected improvements in cognition as detected by the MCCB suggest that patients may have performed particularly poorly at the prerandomization testing time point. Post-traumatic stress disorder is characterized by high sensitivity to stress. The initial phases of a clinical trial with an investigational medication expose study participants to several uncertainties and stressors, including discussing trauma histories with new people (trial staff ), potential medication adverse effects, potential randomization to the inactive placebo arm, repeated phlebotomy, and, in the current study, psychophysiologic and cognitive testing. The stress sensitivity of PTSD patients might contribute to elevated symptom scores and reduced testing performance at study baseline, thereby contributing to apparent placebo response as stress declines as they become more comfortable with the processes of the trial. Conceptualizing placebo effects in PTSD patients in this way may warrant consideration of using single-blind placebo lead-in phases for medication PTSD trials. Although placebo lead-in designs have not proven to enhance drug-placebo signal detection in MDD trials, 28 the particularly pronounced stress sensitivity in PTSD patients suggests that incorporating placebo lead-in periods for PTSD trials may improve signal detection.
When discussing the placebo effect in this particular study, we must consider the nature of the assessments performed in the clinical trial, particularly in reference to PTSD symptoms. In this study, participants may have actually received treatment for PTSD symptoms in the form of exposure-related therapy, through the repeated CAPS evaluations. It is not clear to what extent the women participating in the trial had ever discussed their PTSD symptoms with others. The CAPS involves systematic discussions of current PTSD symptoms, as relevant to the proximal trauma associated with current PTSD symptoms. This patient population is extremely unlikely to have received a systematic course of prolonged exposure therapy; thus, the assessments included in the repeated CAPS assessment may have had an unintended therapeutic effect.
These findings may call for a reevaluation of psychiatric trial protocols to control for trauma reexposure effects, which may lead to unwanted treatment effects in placebo groups. Modest improvements in performance-based measures are not unusual, although a substantial proportion (25%) of participants demonstrated an increase in cognitive performance equivalent to 8 intelligence quotient points on the MCCB. Thus, using performance-based assessments does not obviate placebo effects. One possibility for these substantial improvements with reassessment may be that study participants had minimal previous experience with performance-based psychological assessments. Taking neuropsychological tests can lead to an increase in familiarity and comfort with cognitive assessments at the time of the second assessment.
Furthermore, these findings have implications for future studies using completely novel performance-based assessment paradigms, such as would be expected in the research domain criteria initiative. Considerations to decrease this placebo response would include maintaining a strict script for researchers when communicating with patients to minimize therapeutic discussion with patients. Decreasing eye contact and unspoken positive gestures may help to mitigate comfort and familiarity of the patient with the researchers. Furthermore, testing effects may be minimized with multiple tests being given before starting the medication to ensure an accurate baseline score and decrease retesting phenomena across the drug trial itself.
CONCLUSIONS
Placebo effects are a significant challenge in the conduct of clinical trials for mood and anxiety disorder and are particularly relevant in studies of PTSD, where stress sensitivity may drive high baseline scores that can result in large placebo effect sizes by trial's end. Objective performance-based measures are also susceptible to placebo effects, although to a lesser degree than symptom report indices or rater indices. Modifications to clinical trial designs are necessary to minimize the effects of placebo treatments. These findings have implications for future studies using novel performance-based assessment paradigms, such as those that may find use in studies applying the National Institute of Mental Health Research Domain Criteria initiative. The authors declare no conflicts of interest.
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